GLN-ATOVAQUONE Suspension
Country: Canada
Language: French
Source: Health Canada
Summary of Product characteristics
(SPC)
28-06-2022
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
Atovaquone
Available from:
GLENMARK PHARMACEUTICALS CANADA INC.
ATC code:
P01AX06
INN (International Name):
ATOVAQUONE
Dosage:
750MG
Pharmaceutical form:
Suspension
Composition:
Atovaquone 750MG
Administration route:
Orale
Units in package:
15G/50G
Prescription type:
Prescription
Product summary:
Numéro de groupe d'ingrédients actifs (GIA) :0124073001; AHFS:
Authorization status:
APPROUVÉ
Authorization date:
2022-06-29
Summary of Product characteristics
TABLE OF CONTENTS
MONOGRAPHIE DE PRODUIT - GLN-ATOVAQUONE
.........................................................................................................
AGENT ANTIPROTOZOAIRE
..................................................................................................................................................................
MONOGRAPHIE DE PRODUIT
...............................................................................................................................................................
INDICATIONS ET UTILISATION CLINIQUE
............................................................................................................................................
ESSAI COMPARATIF AVEC LE TMP-SMX
...................................................................................................................................................................
ESSAI COMPARATIF AVEC LA PENTAMIDINE
...........................................................................................................................................................
DONNéES SUR LE TRAITEMENT CHRONIQUE
.........................................................................................................................................................
CONTRE-INDICATIONS
..........................................................................................................................................................................
MISES EN GARDE
...................................................................................................................................................................................
PERSONNES âGéES
.....................................................................................................................................................................................................
NOURRISSONS ET ENFANTS
......................................................................................................................................
Read the complete document
